Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

@article{Holman2014CardiovascularOT,
  title={Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes},
  author={R. Holman and H. Sourij and R. Califf},
  journal={The Lancet},
  year={2014},
  volume={383},
  pages={2008-2017}
}
Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. The evidence-based reduction in risk of microvascular disease with glucose lowering has resulted in guidelines worldwide recommending optimisation of glycosylated haemoglobin, but no trial results have shown unequivocal… Expand
182 Citations
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
  • 70
Current perspectives on cardiovascular outcome trials in diabetes
  • 56
  • Highly Influenced
  • PDF
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
  • 20
  • Highly Influenced
  • PDF
A review of cardiovascular outcome trials in type 2 diabetes.
  • 1
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Effects of intensive glucose lowering in type 2 diabetes.
  • 4,648
  • PDF
Basal insulin and cardiovascular and other outcomes in dysglycemia.
  • 1,241
  • PDF
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
  • 4,816
  • PDF
...
1
2
3
4
5
...